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Objective: The purposes of this study were to evaluate the expression of p16INK4a (referred as to p16) and Ki-67 in 
cervical intraepithelial neoplasia (CIN), and the correlation between high-risk human papillomavirus (HPV) infection 
and the above biomarkers.
Methods: We analyzed 31 patients who were diagnosed with CIN at Kwandong University Myongji Hospital from 
October 2006 to September 2007. CIN specimens (CIN1, 12; CIN2, 6; CIN3, 13) were obtained by colposcopy- 
directed biopsy (CDB) or loop electrical excision procedure (LEEP). The expressions of p16 and Ki-67 were evaluated 
by immunohistochemical methods with antibodies to p16 and Ki67. The immunohistochemical staining results were 
classified into four grades: 0, 1, 2 and 3. HPV genotyping or Hybrid Capture-II test was used to detect high-risk HPV.
Results: The expression of p16 (p＜0.001) and Ki-67 (p=0.003) were positively associated with CIN grade. p16 
expressions increased significantly with high-risk HPV infection (p=0.014), especially HPV type 16 and 58. Ki-67 
expression was not related with high-risk HPV. There was positive correlation between the expression of the p16 and 
Ki-67 (p=0.007).
Conclusion: CIN grade were positively related to the expression of p16 and Ki-67. p16 expressions of high-risk HPV 
specimens significantly increased more than Ki-67. Therefore, in the diagnosis of CIN and high-risk HPV infection, 
p16 can be a useful biomarker.
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INTRODUCTION
  Cervical cancer is still one of the common cancers in Korea. 
Cervical cancer is known to develop from precancerous 
disease, cervical intraepithelial neoplasia (CIN). CIN takes 5 
to 15 years to progress to invasive cancer. By extensive 
epidemiologic and molecular biologic studies, the human 
papillomavirus (HPV) infection is known to be the most 
important etiology of cervical cancer.1 HPV is a double- 
stranded DNA virus and over 120 types of HPV have been 
identified till now. HPV is classified into high-risk and 
low-risk HPV. The persistent infection of high-risk HPV is 
associated with development of cervical cancer.2-4
  HPV is known to induce cervical cancer through uncon-
trolled G1-S transition. The E6 and E7 proteins of high-risk 
HPV inhibit the p53 and pRb proteins which are cell cycle 
regulatory proteins controlling G1-S transition.5 The p16INK4a 
(p16) is a protein which belongs to the inhibitors of cyclin- 
dependent kinase (CDK) 4 family (INK4a family). By inter-
acting with CDK4 and CDK6, p16 inhibits the formation of 
cyclin D/CDK4 and 6 complex, which is a proliferation-sti-
mulating protein. The p16 also functions as a cyclin-dependent 
kinase inhibitor (CDKI) by inhibiting the CDK-induced pho-
sphorylation of pRb.6,7 The phosphorylation of pRb induces 
the release of a transcription factor E2F from the bound form 
of E2F and pRb. The release of E2F results in G1-S transition.8 
Like the p16 protein, HPV infection induces the release of E2F 
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Table 1. The profile of pathology and HPV typing and expression of 
p16 and Ki-67
Patient
Pathology HPV test results p16 Ki-67
number
1 CIN1 Hybrid capture-II 3 1
 positive
2 CIN1 Hybrid capture-II 0 2
 positive
3 CIN1 Negative 0 1
4 CIN1 Negative 0 2
5 CIN1 Negative 0 2
6 CIN1 56 2 1
7 CIN1 Negative 0 2
8 CIN1 54 0 1
9 CIN1 Negative 0 2
10 CIN1 Negative 0 1
11 CIN1 Not taken 0 1
12 CIN1 52 0 1
13 CIN2 39 3 2
14 CIN2 40*, 52, 53 2 2
15 CIN2 Negative 1 2
16 CIN2 35 1 2
17 CIN2 58, 66 3 2
18 CIN2 34*, 39, 59, 66 1 1
19 CIN3 52 3 Not taken
20 CIN3 16 3 2
21 CIN3 31 3 3
22 CIN3 16 3 3
23 CIN3 16, 58 3 3
24 CIN3 Negative 3 2
25 CIN3 16 3 1
26 CIN3 58 3 2
27 CIN3 33 3 3
28 CIN3 16 3 2
29 CIN3 58 3 3
30 CIN3 6*, 16, 58 3 2
31 CIN3 Negative 3 3
*low risk type HPV
through the binding of E7 to pRb. The released E2F stimulates 
the expression of genes which are involved in G1-S transition.9 
The inactivation of pRb by E7 causes the p16 overexpression 
because p16 is regulated by negative feedback of pRb.9-12 Ki-67 
is a well-known cell proliferation marker and which may be 
used for grading CIN.13-15
  To evaluate the clinical values of p16 and Ki-67 expressions, 
we examined the p16 and Ki-67 expressions in CIN and 
investigated the associations of high-risk HPV infection with 
the p16 and Ki-67 expressions. 
MATERIALS AND METHODS
1. Subjects
  Thirty-one patients who underwent a colposcopy-directed 
biopsy or loop electrosurgical excision procedure and were 
diagnosed as having CIN at the Myongji Hospital between 
October 2006 and September 2007 were included in this 
study. Normal cervical tissues which were located next to a 
CIN lesion on a slide were used as controls. 
2. Methods
1) Detection of high-risk HPV
  Tests for high-risk HPV infection were performed at the time 
of the biopsy. Oligonucleotide microarray DNA chip (MyGene 
Inc., Seoul, Korea) or HPV hybrid capture IIⓇ kit (Digene/ 
Abbott, Clopper Road, Gaithersburg, Maryland, USA) were 
used to detect the high-risk HPV. HPV 16, 18, 31, 33, 35, 39, 
45, 51, 52, 53, 54, 56, 58, 59, 66, 68 were considered as the 
high-risk HPV, and HPV 6, 11, 34, 40, 42, 43, 44, 70 were 
regarded as the low-risk HPV.
2) Techniques of immunohistochemical staining and inter-
pretation of staining results
  (1) Techniques of Immunohistochemical staining 
  Formalin-fixed, paraffin-embedded tissue blocks were sliced 
in thickness of 3 um and the tissue sections were mounted on 
silanized slides. Immunohistochemical staining was per-
formed through the indirect biotin streptoavidin method using 
the iVIEWTM DAB Detection Kit (Ventana Medical Systems, 
Tucson, AZ, USA). The sections were deparaffinized in xylene 
and were sequentially washed twice in 100% alcohol and in 
95%, 90%, 80%, and 70% alcohol for two minutes. To increase 
the antigen detection, the slides were immersed in a citrate acid 
solution and were heated for 20 minutes in a microwave. The 
slides were washed with APK Wash Solution (Ventana Medical 
Systems, Tucson, AZ, USA) and were stained using the 
automatic immunohistochemical staining equipment, Ventana 
NexES IHC (Ventana Medical Systems, Tucson, AZ, USA). The 
p16 and Ki-67 staining was performed with 1:25 diluted 
Monoclonal Mouse Antibody p16INK4a protein (Diagnostic Bio-
System, USA) and 1:50 diluted Monoclonal Mouse Antibody 
(DAKOCytomation, Denmark), respectively.
  After the slides were incubated with antibodies for 32 
minutes, the slides were exposed to Diaminobenzidine 
(DAB) for 4 minutes and were counterstained with Mayer's 
Hematoxylene for 4 minutes. DAB and Mayer's Hemato-
xylene which were included in iVIEWTM DAB Detection Kit 
(Ventana Medical Systems, Tucson, AZ, USA) were used for 
staining. All staining procedures were performed at 37oC. 
Stained slides were dried and were covered with glass cover 
slides. For a negative control, non-immune mouse serum IgG 
was used instead of primary antibodies. 
  (2) Interpretation of staining results and statistical analysis
  All slides were examined by two independent reviewers. 
Irrespective of cytoplasmic staining, the cell whose nucleus 
was stained with anti-p16 antibody was regarded as p16 
positive. The percentage of p16 positive cells was used to 
determine the grade of p16 expression. Grade 0 was given 
when the percentage of positive cells was below 1%. Grade 1+ 
and 2+ were assigned when the clustered positive cells were 
J Gynecol Oncol Vol. 19, No. 3:162-168, 2008 Eun Ji Nam, et al.
164
present and the percentage of positive cells was 1-5% and 
5-25%, respectively. Grade 3+ was graded when there were 
diffuse positive cells and the percentage of positive cells was 
greater than 25%. To determine the grade of Ki-67 expression, 
nucleuses of 200 epithelial cells located across the whole 
epithelial layer were examined in a high-power field (×600). 
Ki-67 index was defined as the percentage of Ki-67 positive 
cells. Grade 1+, 2+, and 3+ was given when the Ki-67 index 
was below 5%, 5-30%, and greater than 30%, respectively. 
  The association of CIN grade with high-risk HPV infection and 
p16, Ki-67 expressions were evaluated with the Fisher's exact 
test, Mann-Whitney test, Kruskall-Wallis test, and Pearson's 
correlation test using SPSS 13.0 (Chicago, IL, USA). p values 
smaller than 0.05 were regarded to be statistically significant. 
RESULTS
  Twelve patients with CIN 1 (38.7%), six patients with CIN 
2 (19.4%), and 13 patients with CIN 3 (41.9%) were included 
in this study. The results of the pathologic examination and 
HPV test, the grade of p16 and Ki-67 expression are 
summarized in Table 1 and Fig. 1. The p16 staining was 
performed in 31 patients but Ki-67 staining and HPV tests 
were performed in 30 patients. The p16 expression was not 
observed in 10 of 12 patients with CIN 1 (83.3%), but strong 
p16 expression was detected in all patients with CIN 3 
(13/13). Ki-67 expression was detected in all patients. Seven 
of 12 patients with CIN 1 showed weak Ki-67 expression, but 
6 of 12 patients with CIN 3 had strong Ki-67 expression 
(Table 2). As the CIN grade was higher, stronger p16 and 
Ki-67 expressions were observed (p16, p＜0.001; Ki-67, 
p=0.003; Fig. 2). In addition, the expression level of p16 
positively correlated with that of Ki-67 (p=0.007). 
  HPV test was performed in 30 patients. Two patients 
underwent the HPV hybrid capture-II test and 28 patients 
received the HPV DNA genotyping. Among the 30 patients 
who underwent the HPV test, 21 patients demonstrated 
high-risk HPV infection. Sixteen of 19 patients with CIN 2 or 
3 (84.2%) and five of 11 patients with CIN 1 (45.5%) were 
positive for high-risk HPV (p=0.035; Table 3). HPV 16 was 
Fig. 1. Representative figures of immunohistochemical staining for p16INK4a (A-D) and Ki-67 
(E-G) in dysplastic cervical tissues. (A) 0 expression (CIN 2), (B) 1+ expression (CIN 2), 
(C) 2+ expression (CIN 2), (D) 3+ expression (CIN 3), (E) 1+ expression (CIN 3), (F) 2+ 
expression (CIN 3), (G) 3+ expression (CIN 3) (magnification, ×400).
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Table 3. The status of high-risk HPV infection based on CIN grade
Diagnosis No HPV infection
HPV type Any type of high-risk
HPV infected
p-value*
HPV 16 HPV 52 HPV 58
CIN1 6/11 (54.5%) 0 1 0   5/11 (45.5%)
CIN2 1/6   (16.7%) 0 1 1   5/6   (83.3%)
CIN3 2/13 (15.4%) 6 1 4 11/13 (84.6%)
        9 6 3 5          21 0.035
*p-value is calculated from comparing high-risk HPV infection status related to the grade of CIN
Fig. 2. p16 and Ki-67 expression status according to the grade of 
CIN. The expression of p16 (p<0.001) and Ki-67 (p=0.003) were 
positively associated with CIN grade.
Table 2. Expression status of p16 and Ki-67 related to grade of CIN
Diagnosis
p16 Ki-67
0 1 2 3 0 1 2 3
CIN1 10/12 0 1/12 1/12 0 7/12 5/12 0
(83.3%) (8.3%) (8.3%) (58.3%) (41.7%)
CIN2 0 3/6 1/6 2/6 0 1/6 5/6 0
(50.0%) (16.7%) (33.3%) (16.7%) (83.3%)
CIN3 0 0 0 13/13 0 1/12 5/12 6/12 
(100%) (8.3%) (41.7%) (50.0%)
p-value* <0.001 0.003
*the expression of p16 and Ki-67 were positively associated with CIN grade
the most common type of HPV detected in 31 patients and 
HPV 58, 52 were the second and third most common type of 
HPV. HPV 16 and 58 were detected only in high-grade CIN. In 
three patients, both high-risk and low-risk HPV were identified. 
However, there were no patients who were infected with only 
low-risk HPV (Table 1). Out of nine patients with negative 
HPV test, the p16 expression was not observed in six patients 
(66.7%) and strong p16 expression was detected in two 
patients (22.2%). However, strong p16 expression was 
observed in all patients with HPV 16 or 58 infections (Table 4). 
Among 21 patients with high-risk HPV infection, p16 
expression was not detected in three patients (14.3%) and 
strong expression was identified in 14 patients (66.7%). 
High-risk HPV infection was associated with p16 expression 
(p=0.014; Table 4). The Ki-67 expression was detected in all 
patients. Ki-67 expression was not associated with HPV 
infection or high-risk HPV infection (Table 4). When we 
examined the expression levels of p16 and Ki-67 according to 
the HPV type, the expression level of p16 was higher in 
patients with high-risk HPV infection than in patients without 
high-risk HPV infection (Fig. 3). However, HPV 52 infection 
was not associated with the expression levels of p16 or Ki-67. 
In addition, the expression level of Ki-67 was not associated 
with HPV infection (Fig. 3). 
DISCUSSION
  HPV infection is known as the most important cause of 
cervical cancer. The inhibition of cell cycle regulatory proteins 
by E6 and E7 is known to initiate the carcinogenesis process. 
The p16 is a cell cycle regulatory protein which is the main 
target of HPV, and Ki-67 is a cell proliferation marker. We 
examined the association of the high-risk HPV infection with 
the expression levels of p16 and Ki-67 in patients with CIN. In 
early reports on cell cycle regulatory proteins, the association 
of the CIN grade with the expression level of p16 was unclear. 
However, recent studies reported that the p16 and Ki-67 
expressions were higher in high-grade CIN than in low-grade 
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Fig. 3. p16 and Ki-67 expression status according to the status of HPV infection. p16 expressions increased significantly with high-risk HPV 
infection (p=0.014), especially HPV type 16 and 58. Ki-67 expression was not related with high-risk HPV.
Table 4. p16 and Ki-67 expressions according to the status of HPV infection
HPV infection status
p16 Ki-67
0 1 2 3 0 1 2 3
No HPV infection 6/9 1/9 0 2/9 0 2/9 6/9 1/9 
(66.7%) (11.1%) (22.2%) (22.2%) (66.7%) (11.1%)
Subtype 16 0 0 0 6/6 0 1/6 3/6 2/6 
               (100.0%) (16.7%) (50.0%) (33.3%)
52 1/3 0 1/3 1/3 0 1/2 1/2 0
(33.3%) (33.3%) (33.3%) (50.0%) (50.0%)
58 0 0 0 5/5 0 0 3/5 2/5 
            (100.0%) (60.0%) (40.0%)
Any type of high- 3/21 2/21 2/21 14/21 0 6/20 9/20 5/20 
 risk HPV infection (14.3%) (9.5%) (9.5%) (66.7%) (30.0%) (45.0%) (25.0%)
p-value* 0.014 0.871
*p16 showed significantly different expression status according to the status of HPV 16, 58, and any type of high-risk HPV infection
CIN (Table 5).12,16-21 The results of the recent studies are 
concordant with that of the current study. The mechanism of 
p16 overexpression is still unclear. Some researchers 
hypothesized that the p16 overexpression may be due to the 
removal of p16 inhibition by pRb, which is degraded by E7 
through a ubiquitin-dependent proteinase system.22-24 Several 
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Table 5. Immunoexpression status of p16 and Ki-67 in benign, intraepithelial lesion, and carcinoma of the cervix
Reference Pathology No. of case
Antibody and expression status
p16 Ki-67
Keating, et al16 Normal 24 Strong positive;     0% Upper 2/3; 7.7%
CIN1 24 37.5% 71.4%
CIN2 & 3 37 70.2% 94.7%
Klaes, et al17 Normal 42 Diffuse positive;     0%
CIN1 47   61%
CIN2 32 100%
CIN3 60 100%
SCC 53   98%
Agoff, et al18 Normal 133 p16>75% positive;     4% Ki-67> 2/3 positive;     5%
CIN1 76 12%   18%
CIN2 80 35%   55%
CIN3 113 73%   76%
SCC 46 70%   87%
Wang, et al19 Normal 58 Diffuse positive;     5%
CIN1 75   36%
CIN2 19   63%
CIN3 19 100%
Murphy, et al20 Normal 20 p16>50% positive;     0%
CIN1 38   60%
CIN2 33   52%
CIN3 46   59%
SCC 10 100%
Lorenzato, et al21 Normal 27 p16>25% positive;     0% Ki-67>2/3 positive;   11%
CIN1 29   52%   58%
CIN2 & 3 43   81% 100%
Nam, et al12 Normal 10 Nuclear positive;     0%
CIN1 117   27%
CIN2 44   37%
CIN3 104   62%
SCC: squamous cell carcinoma
studies have reported that the p16 expression increased in 
patients with a high-risk HPV infection.17,25 These findings 
indirectly supported the hypothesis. In the current study, p16 
expression increased in patients with high-risk HPV infec-
tion. In the current study, as the CIN grade was higher, the 
p16 and Ki-67 expressions became stronger. The Ki-67 
expression was not associated with high-risk HPV infection. 
These findings suggest that p16 may be involved in the 
HPV-induced carcinogenesis. To increase the reproducibility 
of diagnosis, Ki-67 may be employed as an objective marker 
because the expression levels of Ki-67 linearly increase as the 
CIN grade is higher. Although Ki-67 may be used as a marker 
for cell proliferation, Ki-67 is thought not to play a role in 
carcinogenesis of cervical cancer.
  The association of HPV type with expression levels of p16 is 
still controversial. Previous studies reported that HPV 16 was 
associated with expression levels of p16.18,20 In the current 
study, the expression level of p16 was increased in patients 
infected with HPV 16, the strongest oncogenic virus. HPV 58 
and 52, whose prevalence are known to be higher in Korea 
than in other countries, are the most common HPV types 
except HPV 16.23 Like HPV 16, HPV 58 is associated with the 
expression levels of p16. Therefore, HPV 58 is thought to be 
related with the development of cervical cancer in Korean 
women. There were only few studies which have investigated 
the association of HPV 58 with p16 overexpression. The p16 
is thought to be related with the carcinogenesis process 
induced by HPV 58. Therefore, further studies on the expre-
ssion of cell cycle regulatory proteins in patients infected with 
HPV 58 are necessary. For a HPV vaccine to be effective in 
Korea, the HPV vaccine should target HPV 52 and 58, in 
addition to the four types of HPV (HPV 16, 18, 6, 11) which 
are already included in the currently available HPV vaccine.
  In low grade CIN, HPV test was negative in 54.5% of 
patients. The hybrid capture-II test may be negative in CIN 1 
because CIN 1 develops from the low-risk HPV. However, 
HPV DNA genotyping which detects all types of HPV was 
performed for most patients in the current study. Therefore, 
the high negative rate of HPV test is thought to be due to the 
insensitivity of HPV test. In addition, there were no patients 
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who were infected with only low-risk HPV. The p16 
overexpression is rare in patients infected with a low-risk 
HPV because E7 of low-risk HPV has lower affinity to pRb 
than that of high-risk HPV.27 
  In conclusion, the expression level of p16 and Ki-67 
increased as the CIN grade was higher. The p16 overexpre-
ssion was associated with a high-risk HPV infection. 
Especially, the p16 overexpression was associated with HPV 
58 infection. Cell cycle regulatory proteins related with p16 
are thought to play a role in carcinogenesis process induced by 
HPV 58.
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